Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy

Conditions

• Lung Non-Small Cell Carcinoma
• Stage III Lung Cancer AJCC v8

Eligibility Criteria

Sex

ALL

Age

60 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Best Practice — OTHER
  Receive usual care
• Biospecimen Collection — PROCEDURE
  Undergo blood and stool sample collection
• Communication Intervention — OTHER
  Receive GA assessment summary and assessment-based recommendations
• Comprehensive Geriatric Assessment — OTHER
  Complete GA
• Electronic Health Record Review — OTHER
  Ancillary studies
• Survey Administration — OTHER
  Ancillary studies

Study Details

This clinical trial tests how well a geriatric assessment (GA) with GA-directed treatment recommendations, compared to GA with usual care, works in identifying risk factors, reducing chemotherapy radiation toxicity and functional decline, and improving the overall quality of life in older patients with non-small cell lung cancer (NSCLC). Older patients with lung cancer undergoing chemotherapy are at an increased risk of adverse outcomes including treatment toxicity and functional and physical consequences. This makes it very challenging for the physicians to balance the benefits against the risk of chemotherapy in older cancer patients. A geriatric assessment may be useful in identifying risk factors for chemotherapy radiation toxicity. Communicating these geriatric assessment findings and assessment-based recommendations to a patient's treating physicians may help them make more informed decisions about treatment options for patients. Making treatment decisions using GA-based recommendations may reduce adverse events and improve outcomes in patients receiving treatment for NSCLC.

Key Dates

Start date

May 21, 2024

Status verified

Jul 2025

Primary completion

Jul 19, 2026

Completion

Jul 19, 2026

Study Design

Enrollment

180 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Arms

• Experimental: Arm I (GA intervention)
  Patients complete a geriatric assessment. Patients and physicians receive the geriatric assessment summary and assessment-based recommendations, which are provided prior to beginning chemotherapy and radiation, at the midpoint of chemotherapy and radiation treatment, and at the end of treatment. Patients also undergo blood and stool sample collection during screening and on study.
• Active Comparator: Arm II (usual care)
  Patients complete a geriatric assessment, but information other than clinically significant cognitive impairment and depression is not provided to the oncology teams, per usual care. Patients also undergo blood and stool sample collection during screening and on study.

Primary Outcome Measure

Incidence of grade 3-5 non-hematologic toxicities [ Time Frame: At 6 months from treatment initiation ]

Locations (3)

Find similar trials in Duarte, CA

Related Studies

• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  PHASE3 · Recruiting · National Cancer Institute (NCI) · Anchorage, Alaska
• Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
  PHASE1 · Recruiting · Ohio State University Comprehensive Cancer Center · Duarte, California
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
  PHASE2 · Recruiting · National Cancer Institute (NCI) · Buena Park, California
• Quality of Life Intervention to Inform Patient Decision-Making in Early-Stage Lung Cancer
  Recruiting · Roswell Park Cancer Institute · Buffalo, New York